
Building an Improved Understanding of Cancer Cost Accumulation

A pragmatic approach to costing cancer across tumour types and sub-groups of cohorts

A Woolmore¹, E Drage¹, T Pope¹, D Simpson¹, T Welchman¹, S McClelland², J Flynn² ¹ Monitor Deloitte, ² Macmillan Cancer Support

Overview of population subgroups for patients Background



Growth in cancer incidence¹ combined with increased survival rates is driving substantial growth in the survivorship population in the UK². This, in combination with continued pressure on NHS spending, will put unprecedented strain on the resources allocated to treat cancer. However, there is a relatively limited body of evidence on understanding the drivers of cost accumulation for cancer patients. This study aims to begin to address this in a pragmatic way.

Method

Pseudo-anonymised inpatient, outpatient and A&E HES data were used to identify cohorts of patients across eight tumour groupings³. Subgroups were created to reflect complexity and the length of time they continued to use hospital services. Finally activity for these patients was categorized into seven types of cancer treatment including a best effort costing of chemotherapy and radiotherapy⁴.


Broad patterns of segment costs by simpler and more complex cases,

Results

Overall, there was a substantial


Analysis of 'dependent at 4+ years' subgroup, colorectal cancer


Overview of cost drivers



cross major cancers

Average total revenue per patient, split by simpler vs more complex and shown by length of service use






Increasing financial impact of noncancer issues for cancer survivors, cross major cancers


% of revenue which is not cancer related, split by simpler vs more complex and shown by length of service use

variance in cost accumulation across patient groups, driven the complexity of their by cancer primarily due to differing chemotherapy When costs. comparing the sub groups within cancers, or across similar see cancers, we patterns Of relative cost non-linear variation i.e. а relationship between cost and length of service use with lower costs for patients with <1 year of service use and those who survive and use healthcare services through the end of the period of analysis.

Cumulative % breakdown, share of total Trust tariff revenue



Conclusion



Note: "Cancer-related" defined by cancer ICD10 / OPCS codes in any of first three diagnosis/procedure positions; weighted average per patient taken across all cohorts and dependency groups from 2007-2010; all other caveats apply; tumour groupings used: Brain & CNS (primary only), Breast, Colorectal, Head and Neck, Lung, Prostate Bladder & Renal, Upper GI, Other; Source: HES 2006-12, Monitor analysis



This pragmatic approach to costing cancer hospital activity reveals interesting insights into cancer populations and is a useful tool in aiding cancer system strategy development.

References

[1] Mistry M, Parkin DM, Ahmad A, et al. Cancer incidence in the UK: Projections to the year 2030. Br J Cancer 2011;105(11):1795-803.

[2] Maddams et al. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer. 2012 Sep 25;107(7):1195-202

[3] Using ICD-10 coding – groups chosen were: Breast; Brain & CNS; Colorectal; Haematological; Head & Neck; Lung; Prostate, Bladder & Renal; Upper GI; and Other [4] All HES data grouped into HRGSs using 2010-11 FY groupers (NHS IC) and subsequently costed against National Reference Costs 2010-11, with Trust tariff revenue applied from National Tariff 2010-11; chemotherapy and radiotherapy activity identified through a HRG, OPCS and consultant treatment speciality algorithm and, because largely off-tariff, assigned a revenue equal to cost at the event level